Formulation A GS-248 + Formulation B GS-248
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetic
Conditions
Pharmacokinetic
Trial Timeline
Mar 31, 2020 → May 27, 2020
NCT ID
NCT04617509About Formulation A GS-248 + Formulation B GS-248
Formulation A GS-248 + Formulation B GS-248 is a phase 1 stage product being developed by Gesynta Pharma for Pharmacokinetic. The current trial status is completed. This product is registered under clinical trial identifier NCT04617509. Target conditions include Pharmacokinetic.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetic were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04617509 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetic